Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



RADCAL
SuperSonic Imagine
RTI ELECTRONICS AB

Channels

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.